Skip to content
10-Q

Quarterly Report

Insight Molecular Diagnostics Inc. IMDX

0000950170-25-069213

← back to feed
Filed
May 12, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 5, 2025 28.6M sh
Cash And Equivalents Q1 2025 · Mar 31, 2025 $31.03M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $8.64M
Current Liabilities Q1 2025 · Mar 31, 2025 $9.68M
Current Liabilities Q1 2025 · Dec 31, 2024 $7.28M
Total Liabilities Q1 2025 · Mar 31, 2025 $50.14M
Total Liabilities Q1 2025 · Dec 31, 2024 $47.36M
Current Assets Q1 2025 · Mar 31, 2025 $36.26M
Current Assets Q1 2025 · Dec 31, 2024 $11.76M
Total Assets Q1 2025 · Mar 31, 2025 $60.36M
Total Assets Q1 2025 · Dec 31, 2024 $35.08M
Shares Diluted Q1 2025 · Mar 31, 2024 8.26M sh
Capex Q1 2025 · Mar 31, 2024 $24K
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$3.83M
Stockholders Equity Q1 2025 · Mar 31, 2024 $11.59M
Stockholders Equity Q1 2025 · Dec 31, 2023 $20.47M
Eps Diluted Q1 2025 · Mar 31, 2024 −$1.13
Eps Basic Q1 2025 · Mar 31, 2024 −$1.13
Sga Expense Q1 2025 · Mar 31, 2024 $2.67M
Rd Expense restated Q1 2025 · Mar 31, 2024 $2.31M
Net Income Q1 2025 · Mar 31, 2024 −$9.13M
Operating Income Q1 2025 · Mar 31, 2024 −$9.27M
Gross Profit restated Q1 2025 · Mar 31, 2024 $45K
Cost Of Revenue restated Q1 2025 · Mar 31, 2024 $109K
Revenue Q1 2025 · Mar 31, 2024 $176K